Fitbit, Inc., Livongo and ResMed are Dominating the Global Digital Therapeutic (DTx) Market in 2020

Global Digital Therapeutic (DTx) Market is expected to grow with the CAGR of 23.4% in the forecast period of 2021 to 2028. The years considered for study are as mentioned below.

Access Full Report @

Global digital therapeutic (DTx) market is a highly consolidated market, which includes specific number of key players. The market has witnessed increased strategic developments owing to favourable market scenario.    

The major players dealing in global digital therapeutic (DTx) market are introducing strong range of products provider along with launching new products and adopting strategic initiative such as acquisition, agreement into the market. This helped companies to maximize the sales with enhanced product portfolio. For instance, in September 2020, Fitbit, Inc. received regulatory clearance in both the United States and Europe for ECG App to Identify Atrial Fibrillation (AFib). This will provide company more potential and increase the customers.

Fitbit is the dominating player in global digital therapeutic (DTx) market. The other key players existing in the market includes Livongo, ResMed, Omada Health, Inc., Noom, Ginger, Happify, Welldoc, Inc., Samsung, Gaia, Inc., Atentiv, Mango Health, Natural Cycles, Cognifit, Cognoa, Kaia Health, Wellthy Therapeutics, Mindstrong Health, Smart Patient GMBH, Ayogo Health, Better Therapeutics, 2morrow, Canary Health, Click Therapeutics, Pear Therapeutics, Voluntis, Akili Interactive Labs, among others.

Digital Therapeutic (DTx) MarketFitbit, Inc.

Fitbit, Inc. was incorporated in 2007 and is headquartered in San Francisco, U.S. The company is focused to empower and provide a healthier, more active life. The company offers to design products and experiences that fit seamlessly into life so to achieve health and better fitness goals. It provides products like watches, trackers and more products for healthy life style.

  • In March 2020, Fitbit, Inc. had conducted Integrating Fitbit wearable devices into diabetes care leads to specific improvements in blood glucose and HbA1C, finds Health2Sync clinical study in Taiwan. The product will provide more services to diseases. The company will gain more consumers and will increase in size and value.

The company has presence across North America, Europe and Asia-Pacific.


Livongo headquartered in Mountain View, California in United States was incorporated in 2008. The company is the consumer of digital health that empowers people with chronic diseases to live good life. The company has also developed full brand-new approaches for diabetes management that would include the brand-new technology with proper coaching.

  • In October 2020, Livongo entered into a partnership with Guidewell Mutual Holding Corporation. With this, Livongo will have access to its select members. Livongo will be able to access Guidewell consumers with diabetes and will help plan their health care journey.  The members will have an end-to-end virtual care experience including connected devices, advanced data science, and telehealth. This will help the company in gaining more customers.

The company has wide presence across North America.


ResMed was founded in 1989 and is headquarter in California, United States. The company is engaged in building global innovation in sleep and respiratory care in order to improve the 250 million lives without the out of- hospital care.

  • In August 2020, ResMed collaborated with Novartis and connected the Propeller Digital Health platform to Enerzair and Atectura Breezhaler once-daily drugs available outside the U.S. for asthma treatment. This collaboration is an important step forward in improving patient outcomes and increasing compliance with chronic respiratory illnesses.  This will increase the market value of the company.

The company has wide presence across North-America, Asia-Pacific and Europe.